|Bid||0.1050 x 0|
|Ask||0.1100 x 0|
|Day's range||0.1000 - 0.1320|
|52-week range||0.0490 - 0.1450|
|Beta (5Y monthly)||2.67|
|PE ratio (TTM)||N/A|
|Earnings date||24 Feb 2023|
|Forward dividend & yield||N/A (N/A)|
|1y target est||0.15|
ImpediMed ( ASX:IPD ) First Half 2023 Results Key Financial Results Revenue: AU$5.66m (up 8.8% from 1H 2022). Net loss...
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
ImpediMed Limited (ASX: IPD) is pleased to announce a poster showing that breast cancer patients receiving early detection of lymphedema using ImpediMed's L-Dex® technology and intervention had statistically higher rates of lymphedema progression-free survival through three years compared to using tape measure was presented at the 2022 San Antonio Breast Cancer Symposium on December 6-10, 2022 in San Antonio, Texas.